Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.

Show more authors
+ 18
Reinhard Dummer
Shahneen Sandhu
Wilson H Miller
Marcus O Butler
Matthew H Taylor
Lucie Heinzerling
Christian U Blank
Eva Muñoz Couselo
Howard A Burris
Michael A Postow
Bartosz Chmielowski
Mark R Middleton
Carola Berking
Jessica C Hassel
Anja Heike Gesierich
Cornelia Mauch
Joseph F Kleha
Anna Polli
Allison S Harney
Alessandra di Pietro
Paolo A Ascierto

More about this publication

Future oncology (London, England)

Pages 1-19
Publication date 31-03-2026

Full text links

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.